Rangering i aksjer
#12604
CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery,... CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014.
Aksjekurs
$9.09
Sist synkronisert: 2023-06-23
Handel CTI BioPharma Corp. (CTIC)
Pris CTIC pris med markedsverdi på B
Markedsverdi av CTI BioPharma Corp.(CTIC)
Markedsverdi: $567.77M
Per August 2026 har CTI BioPharma Corp. en markedsverdi på $567.77M. Dette gjør CTI BioPharma Corp. til det 12604th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for CTI BioPharma Corp. fra 1997 til 2026
CTIC sammenlignet med topp 5 mest populære stocks
| Pris på CTIC |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.264T
|
+927,011.86%
|
|
|
|
|
$4.701T
|
+827,923.98%
|
|
|
|
|
$4.177T
|
+735,615.87%
|
|
|
|
|
$3.817T
|
+672,249.31%
|
|
|
|
|
$2.866T
|
+504,740.75%
|
